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Sequencing of serial isolates of extensively drug-resistant
tuberculosis highlights how drug resistance develops
within a single patient and reveals unexpected levels of
pathogen diversity.patient [2]. This adds to an emerging body of evidenceTuberculosis (TB) remains a crucial public health prob-
lem, with increasing drug resistance posing a challenge
to current control efforts. Treatment regimens for drug-
susceptible TB are onerous, requiring a minimum of six
months of treatment with four antitubercular drugs. There
are patients who develop multi-drug-resistant (MDR), ex-
tensively drug-resistant (XDR) and totally drug-resistant
(TDR) forms, which are successively more difficult to
treat. In these circumstances, treatment regimens involve
the use of a larger number of less-effective drugs, which
have a narrower therapeutic margin.
In many bacteria, drug-resistance determinants are carried
on mobile genetic elements. However, in Mycobacterium
tuberculosis (Mtb), drug resistance is exclusively associated
with point mutations and chromosomal rearrangements.
Poor or intermittent therapy has long been thought to
be the major explanation for drug resistance, and it is
believed that drug-resistant strains develop through the
sequential fixation of a small set of mutations, such that
the pathogen samples only a small proportion of pos-
sible evolutionary paths [1].
The application of whole-genome sequencing (WGS)
has revealed previously underappreciated levels of genetic
diversity within circulating Mtb populations, and the
implications of this diversity for transmission and dis-
ease outcomes are increasingly being acknowledged.* Correspondence: r.j.wilkinson@imperial.ac.uk
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medium, for 12 months following its publicatio
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creativecommons.org/publicdomain/zero/1.0/)By contrast, mycobacterial heterogeneity within a sin-
gle host, and any concomitant biological or clinical sig-
nificance, has been explored but seldom documented.
In a study published in this issue of Genome Biology,
Eldholm and colleagues apply WGS to investigate the
evolution from drug-sensitive to XDR-TB within a single
that suggests that intra-host microbial diversity is sub-
stantial and might have significant consequences when
inferring transmission. There are few instances, if any, in
the literature where this has been investigated in such
detail.Mapping drug-resistant tuberculosis in a single
patient
The study team took advantage of nine serial bacterial
isolates collected from a single patient, from the time of
first diagnosis of drug-susceptible TB through to the
development of XDR-TB. The infection ultimately re-
solved following the addition of linezolid to the treatment
regimen - linezolid is known to be a moderately effective
treatment for drug-resistant TB when other options have
failed [2]. Illumina sequencing was applied to the isolates,
which were collected over a period of 42 months, achiev-
ing a high depth of coverage. By relaxing the stringency of
filters applied to detect single-nucleotide polymorphisms
(SNPs), the authors observed unexpected levels of hetero-
geneity within individual samples. It is worth mentioning
that DNA was not extracted from single colonies - instead
‘loopfuls’ of bacterial cells were harvested for DNA. This
approach allowed the group to detect SNPs present at a
frequency of approximately 25% at sites with a minimum
read-depth of 50. Of the 35 SNPs identified in this way, 20
were transient and 15 eventually became fixed. Twelve of
the observed mutations were associated with drug resist-
ance, and phenotypic resistance was observed at the same
time that genotypic resistance emerged.Central Ltd. The licensee has exclusive rights to distribute this article, in any
n. After this time, the article is available under the terms of the Creative Commons
/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
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strain, multiple resistance alleles were observed for antitu-
bercular drugs throughout the course of infection, with
the exception of rifampicin and kanamycin [2]. The levels
of micro-heterogeneity reported are consistent with those
of previous studies [3, 4].
These observations suggest that, at any given time, there
might be significant Mtb diversity within a single patient.
High levels of diversity could affect the accurate interpret-
ation of WGS data that are used to infer transmission.
Current WGS of Mtb requires subculture of the bacilli
from patient samples to ensure that sufficient DNA is
available for analysis, and bacterial subpopulations that
are not culturable are not captured during downstream
sequencing [5]. Moreover, one cannot be certain that a
single sputum sample represents all regions of the lung;
indeed significant intra-lesional heterogeneity has been
observed in humans [6]. Therefore, intra-patient variabil-
ity could be even higher than reported by the aforemen-
tioned studies and might not be detectable by current
WGS approaches.
Advantages of adaptability: survival of the fittest
By virtue of access to multiple samples from the entire
course of disease, Eldholm and colleagues were able to
calculate mutation rates for the sample set [2]. The re-
sults are unique in that they suggest that non-resistance
mutations hitchhike with, or link to, resistance SNPs to
become fixed within the population. This phenomenon
could partly explain the high numbers of SNPs recently
found to occur in global collections of drug-resistant
Mtb isolates [7].
When the authors removed both resistance and hitch-
hiking mutations from the analysis, they found that the
mutation rate was only slightly higher than that recently
reported in cohorts with drug-susceptible disease [8].
Their findings suggest that the selective pressure con-
ferred by antibiotics provides Mtb with an opportunity
to diversify and adapt. Drug resistance represents a read-
ily measureable determinant of genetic change because
its effects can be attributed to a set of discrete SNPs.
There are additional factors whose impact on the gen-
ome of Mtb are not well established, such as the vaccin-
ation status of individual patients or their status with
respect to human immunodeficiency virus (HIV). These
factors are much more complicated to consider, but im-
portant and interesting nonetheless.
Significantly, Eldholm and colleagues complemented
genomic data with phenotypic evaluation of the fitness
of isolates with different resistance mutations [2]. Results
of growth-rate measurements in the presence of the drug
indicated that the fittest strains contained mutations that
eventually became fixed. While there may be caveats when
assaying Mtb fitness under laboratory conditions, theseresults provide further support for the notion that resist-
ance mutations with the lowest fitness costs will eventu-
ally become fixed within a population.
Additionally, through RNA sequencing of a subset of sam-
ples, the authors observed a stable change in transcriptional
patterns as drug resistance emerged [2]. Genes that were
differentially regulated included those involved in efflux
and synthesis of cell-wall components. The targets of anti-
biotics are, by definition, functionally essential [1], and the
changes in transcriptional remodeling could indicate an im-
portant mechanism that facilitates adaptation to the fitness
costs of having mutations in multiple essential genes [2].
For the future
The study by Eldholm and colleagues has provided valu-
able insights into the evolution of Mtb drug resistance
within a single host, and in the process it has demonstrated
the considerable diversity and adaptability of the pathogen
[2]. As any good study should, it also raises important
questions for further investigation.
The SNPs identified in the current study were validated
by PCR [2] - however, the use of a low threshold to assign
a SNP as genuine imparts the possibility of false positives.
Additionally, the sequencing of DNA from batches of cells
cannot determine the single-cell origin of specific muta-
tions, and therefore epistatic interactions, which have been
shown to be important in the evolution of drug resistance
in Mtb [9], cannot be investigated by this approach. However,
the application of WGS technologies to areas such as culture-
independent [10] and single-cell sequencing will provide
the necessary tools to investigate these issues further.
Although the phenotypic implications of resistance
mutations have been extensively studied [1], the biological
and clinical significance of the hitchhiking mutations is
largely unknown. Nevertheless, the study by Eldholm
et al., which was conducted in in Norway [2], is a striking
reminder that TB drug resistance can quite easily develop,
even within the context of very low TB rates in a well-
functioning control program. It will be of vital importance
to determine similarly how micro-heterogeneity influences
disease outcomes and treatment efficacy in regions where
a high burden of TB and elevated infection pressure might
result in unique inter- and intra-host-strain competition
dynamics [5].
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